Navigating chaos and leapfrogging to Pharma 5.0 with ontological honesty and epistemic humility

Abstract: Pharmaceutical manufacturing remains constrained by legacy paradigms that collapse engineered systems into static legal descriptors and struggle to integrate real‑world evidence. Geopolitical instability, supply‑chain fragility, climate‑driven disruption, declining institutional trust and the accelerating influence of generative artificial intelligence expose that constraint as an epistemic ceiling. This Perspective outlines a professional path for leapfrogging toward a patient‑centric Pharma 5.0 paradigm grounded in ontological honesty and epistemic humility. The argument traces this ceiling across three layers—the individual practitioner, the quality system and the broader ecosystem—and places Deming’s System of Profound Knowledge, Kegan’s orders of consciousness and McGilchrist’s hemispheric account alongside the classical sequence of the nafs and a heart‑centered posture of practice (Dil Se).  Leapfrogging is a knowledge strategy before it is a technology strategy. Recent United States hearings and independent quality‑scoring efforts reveal an ontology capable of detecting divergence yet unable to revise certified reality. Pakistan and the broader Global South live under the same ceiling, shaped by high generic volumes and thin margins. Thailand’s May 2025 registration of a domestically developed trastuzumab biosimilar demonstrates capability‑first sequencing; a subsequent United States draft guidance issued on 29 October 2025—proposing that comparative efficacy studies may be unnecessary when analytical comparability is high—confirms the direction of that sequence rather than authorizing it after the fact. Preparing for Pharma 5.0 requires unlearning certain validated habits, cultivating sovereignty of judgment before sovereign infrastructure and building quality systems capable of revising their own descriptions.